In 2001, CRI and Ludwig Cancer Research teamed up to create a centralized, coordinated, integrated network of clinical trial sites with expertise in immunological monitoring called the Cancer Vaccine Collaborative (CVC). The CVC established a system of parallel, early-phase clinical trials where investigators in the US, Europe, Japan, and Australia freely share their data with the goal of accelerating the pace of clinical discovery. Ludwig continues to provide clinical trials management to CRI's central clinical strategy, the Clinical Acclerator.

*Immunotherapy results may vary from patient to patient.